〔Abstract〕 Objective To investigate the effect of sucralfate suspension in the adjuvant treatment in patients of raised erosive gastritis (REG). Methods A total of 94 REG patients admitted to Quanzhou Guangqian Hospital from May 2019 to May 2020 were selected and divided into control group and observation group by random number table method, with 47 cases in each group. The control group was treated with omeprazole, and the observation group was additionally treated with sucralfate suspension. The levels of inflammatory factors, pepsin, gastric mucosa level and adverse reactions in the two groups were observed. Results There were no significant differences in tumor necrosis factor-α (TNF-α), interleukin-10 (IL-10) and interleukin-8 (IL-8) between the two groups before treatment and 8 weeks after treatment (P > 0.05). After 8 weeks of treatment, the levels of TNF-α, IL-10 and IL-8 in the two groups were decreased, the differences were statistically significant (P < 0.05). After 8 weeks of treatment, the levels of gastrin-17 (GAS-17), pepsinogen Ⅰ (PG Ⅰ) and PG Ⅰ /PG Ⅱ (PGR) in the two groups were significantly higher than before treatment, while the level of pepsinogen Ⅱ (PG Ⅱ) was lower than before treatment. The levels of GAS-17, PG Ⅰ and PGR in observation group were higher than control group, while the PG Ⅱ value was lower than control group. The differences were statistically significant (P < 0.05). After 8 weeks of treatment, the levels of KI-67, fibroblast growth factor (bFGF) and epidermal growth factor (EGF) in the two groups were significantly lower than before, and the levels of KI-67, bFGF and EGF in observation group were lower than control group, the differences were statistically significant (P < 0.05). The incidence of adverse reactions was 8.51% in the observation group and 12.77% in the control group, and there was no significant difference between the two groups (P > 0.05). Conclusion Sucralfate suspension can effectively improve the gastric mucosal status and gastric protein level of patients with REG, reduce the level of inflammatory factors, and do not increase the adverse drug reactions.